CervoMed Inc. reported its financial results for the second quarter ended June 30, 2025, on August 11, 2025. The company highlighted the positive 32-week data from the Phase 2b RewinD-LB Trial Extension phase, showing a substantial reduction in clinically significant worsening and a significant reduction in plasma glial fibrillary acidic protein (GFAP) levels.
As of June 30, 2025, CervoMed held approximately $33.5 million in cash, cash equivalents, and marketable securities. This, combined with the remaining $2.9 million from the NIA Grant, is projected to fund operating expenses and capital expenditure requirements for at least twelve months from the 10-Q filing date of August 8, 2025.
For the six months ended June 30, 2025, the net loss was $11.15 million, an increase from $4.83 million in the prior year period. Research and development (R&D) expenses surged by $3.36 million, or 51%, to $9.95 million, primarily due to intensified CMC activities, expanded non-clinical studies, and increased outsourced CRO expenses for new clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.